已收盤 11-20 16:00:00 美东时间
-0.190
-2.40%
Moleculin Biotech ( ($MBRX) ) has provided an announcement. On November 18, 202...
11-18 21:55
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(9.59) per share which missed the analyst consensus estimate of $(8.53) by 12.43 percent. This is a 43.59 percent increase over losses of $(17.00) per share from the same period last year.
11-16 20:36
Moleculin Biotech, Inc. announced the grant of an Australian patent (No. 2020303572) for the preparation of preliposomal Annamycin lyophilizate, enhancing intellectual property protection for its formulation technology. This patent, along with others in the U.S., Canada, China, and other countries, reflects Moleculin's global IP strategy. Annamycin, an investigational anthracycline, is being developed for treating acute myeloid leukemia and other...
11-12 13:37
Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander Annamycin achieves substantially higher pancreatic tissue exposure than doxorubicin, offering a potential explanation...
11-11 03:48
Moleculin Biotech announced preclinical data showing Annamycin combined with PD-1 checkpoint blockade extended survival in pancreatic cancer models. The study demonstrated Annamycin achieves higher pancreatic tissue exposure than doxorubicin and enhances CD8+ T cell infiltration, contributing to its antitumor activity. The findings suggest potential for Annamycin in treating pancreatic cancer and other immunologically cold tumors. Moleculin plans...
11-10 19:45
Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid le...
10-30 20:43
Moleculin Biotech, Inc. has completed dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). The trial involved 90 fully treated, randomized, double-blind patients, providing data to support optimal Annamycin dose selection for Part B. The study includes balanced representation of AML patients who failed 7+3...
10-30 12:40
10月21日,Moleculin Biotech Inc.(MBRX)收涨16.79%,报6.19美元,成交额79.15万美元,市值1.26亿美元。 行情数据...
10-21 06:58
Filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s co...
10-16 21:21
Moleculin Biotech ( ($MBRX) ) has issued an announcement. On September 29, 2026...
09-29 21:16